Trial · NCT00410813
Results by group102
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 102
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival | Dasatinib, 100 mg, Daily | 10.3 | 95% Confidence Interval 8.4 to 16.7 | weeks | |
| Progression-free Survival | Dasatinib, 70 mg, Twice Daily | 15.3 | 95% Confidence Interval 8.7 to 20.1 | weeks | |
| Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Dasatinib, 100 mg, Daily | Partial Response | 1 | participants | |
| Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Dasatinib, 70 mg, Twice Daily | Partial Response | 0 | participants | |
| Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Dasatinib, 100 mg, Daily | Stable/No Response | 14 | participants | |
| Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Dasatinib, 70 mg, Twice Daily | Stable/No Response | 18 | participants | |
| Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Dasatinib, 100 mg, Daily | Increasing Disease | 20 | participants | |
| Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Dasatinib, 70 mg, Twice Daily | Increasing Disease | 10 | participants | |
| Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Dasatinib, 100 mg, Daily | Assessment Inadequate | 6 | participants | |
| Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Dasatinib, 70 mg, Twice Daily | Assessment Inadequate | 10 | participants | |
| Circulating Tumor Cells (CTC) Response Rate | Dasatinib | 4 | participants | ||
| Change in Serum Bone Turnover Markers Over Time -- NTx | NTx at Baseline | 21.84 | Standard Deviation 12.32 | nM BCE | |
| Change in Serum Bone Turnover Markers Over Time -- NTx | NTx at 4 Weeks | 19.23 | Standard Deviation 11.32 | nM BCE | |
| Change in Serum Bone Turnover Markers Over Time -- NTx | NTx at 8 Weeks | 12.88 | Standard Deviation 13.09 | nM BCE | |
| Change in Serum Bone Turnover Markers Over Time -- BAP | BAP at Baseline | 24.07 | Standard Deviation 15.95 | ug/L | |
| Change in Serum Bone Turnover Markers Over Time -- BAP | BAP at 4 Weeks | 24.35 | Standard Deviation 13.94 | ug/L | |
| Change in Serum Bone Turnover Markers Over Time -- BAP | BAP at 8 Weeks | 25.61 | Standard Deviation 14.05 | ug/L | |
| Change in Serum Bone Turnover Markers Over Time | Serum Biomarker at Baseline | DKK | 1157.64 | Standard Deviation 1465.83 | pg/mL |
| Change in Serum Bone Turnover Markers Over Time | Serum Biomarker at 4 Weeks | DKK | 1470.50 | Standard Deviation 1985.09 | pg/mL |
| Change in Serum Bone Turnover Markers Over Time | Serum Biomarker at 8 Weeks | DKK | 1575.05 | Standard Deviation 1993.44 | pg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00410813/results